Deal-hungry Ipsen is at it again, pledging just over $1 billion for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere Zaiming, that is due to start clinical testing ...
Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...
BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, and China, that involves near-term payments of $90 million with another ...
Moderna's mRNA-based pandemic flu vaccine – which had federal funding pulled earlier this year amid an increasingly vaccine-sceptic stance by the Trump administration – has been thrown a lifeline by ...
Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made available ...
In the latest of a flurry of announcements ahead of the holiday period, CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and ...
The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...
In labs, water consumption and single-use plastics like pipette tips can contribute to environmental impact. Lab equipment ...
A first-of-its-kind partnership between medicines regulators in the UK and Singapore could allow patients in both countries to access new medical advances more quickly. The UK's Medicines and ...
The FDA has revealed the latest element in its adoption of AI, an agentic AI platform that agency staffers can use to streamline complex tasks. According to the US regulator, agentic AI – autonomous ...
The FDA has published new guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs), in the latest stage of an ongoing effort to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback